PaxMedica Holds Meeting of Scientific Advisory Board
PaxMedica, Inc. (Nasdaq: PXMD) held a Scientific Advisory Board meeting from March 10-12, 2023, adding several leading experts in autism spectrum disorder (ASD) to its board. These experts include Dr. Robert Naviaux and Dr. Robert Findling, among others. The purpose of the meeting was to advance the development of suramin, a potential treatment for core symptoms of ASD. The company anticipates launching international multicenter clinical trials for suramin in 2024. PaxMedica focuses on anti-purinergic drug therapies for neurologic disorders, including ASD and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
- Addition of key opinion leaders in ASD to the Scientific Advisory Board enhances credibility.
- Expert insights gathered for the clinical development of suramin may strengthen research direction.
- Anticipated international clinical trials for suramin in 2024 could expand market potential.
- Dependence on suramin’s success for future growth introduces uncertainty.
- The timeline for clinical trials may face delays or obstacles affecting development.
Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S.
TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that it held a Scientific Advisory Board meeting on March 10-12, 2023. A number of new members have been added to the board, which consists of many key opinion leaders in autism spectrum disorder (ASD) in the United States including:
- Dr Robert Naviaux, Professor of Medicine, Pediatrics, and Pathology, at the University of California, San Diego
- Dr. Robert Findling, Chair of the Department of Psychiatry, at Virginia Commonwealth University School of Medicine
- Dr. Alice Mao, Professor of Psychiatry and Behavioral Sciences, at Baylor College of Medicine
- Dr. Constance Smith-Hicks, Associate Professor of Neurology at Johns Hopkins University and neurologist and research scientist at the Kennedy Krieger Institute
- Dr. Andrew J. Cutler, Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and Chief Medical Officer, Neuroscience Education Institute
- Dr. Vladimir Maletic, Clinical Professor, Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine
- Dr. Michael Aman, Professor Emeritus, The Ohio State University Department of Psychology
- Dr. Rakesh Jain, Clinical Professor, Department of Psychiatry Texas Tech University School of Medicine - Permian Basin
The meeting was hosted by PaxMedica’s Chief Medical Officer, Stefan Schwabe, MD, PhD, who commented, “We convened some of the country’s leading experts in autism spectrum disorder in support of our efforts to bring suramin to the next phase of clinical trials. We continue to be very excited about studying a product for the potential treatment of the core symptoms of autism spectrum disorder.”
Dr. Robert Naviaux added, “At the scientific advisory board meeting this weekend, experts from many different areas of medicine came together to share their thoughts on how suramin may work in ASD and how it might work in several other complex disorders. What emerged was a clear vision for the next steps needed to test suramin in autism. This is expected to be done in a series of international, multicenter, clinical trials that are projected to begin in 2024.”
About PaxMedica
PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including Autism Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (“COVID-19”). One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome, a clinical diagnosis in individuals who have been previously infected with COVID-19. For more information, please visit: www.paxmedica.com
Forward-Looking Statements
This press release contains “forward-looking statements.” Statements contained in this press release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding our anticipated development and operating plan, achievement of anticipated milestones, planned research and development efforts and other matters regarding the Company’s business strategy, use of capital, and plans and objectives for future operations. Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement, most recent quarterly reports, and other filings with the U.S. Securities and Exchange Commission.
Contacts:
Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
(646) 863-6341
FAQ
What is the purpose of the Scientific Advisory Board meeting held by PaxMedica on March 10-12, 2023?
Who are some of the key opinion leaders added to PaxMedica's Scientific Advisory Board?
What are the expected outcomes of the suramin clinical trials mentioned in the press release?
What conditions does PaxMedica focus on in its drug development?
